![]() With regards to medication management, for patients with clinical cardiovascular disease, a sodium–glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. These include additional focus on lifestyle management and diabetes self-management education and support. ![]() A systematic evaluation of the literature since 2014 informed new recommendations. The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 20, on the management of type 2 diabetes in adults.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |